SAN DIEGO / Aug 19, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend two upcoming investor conferences.
Morgan Stanley 22nd Annual Global Health Conference – New York, NY
On Thursday, September 5, 2024, QuidelOrtho’s President and Chief Executive Officer, Brian Blaser, and Chief Financial Officer, Joseph Busky, are scheduled to participate in a fireside chat at 7:00 a.m. ET / 4:00 a.m. PT.
2024 Baird Global Healthcare Conference – New York, NY
On Tuesday, September 10, 2024, Messrs. Blaser and Busky are scheduled to participate in a fireside chat at 9:40 a.m. ET / 6:40 a.m. PT.
Interested parties can access the live webcasts and replays of both events in the “Events & Presentations” section of the “Investor Relations” page of QuidelOrtho’s website at https://ir.quidelortho.com/.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.
Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.
QuidelOrtho is advancing diagnostics to power a healthier future.
For more information, please visit www.quidelortho.com.
| Last Trade: | US$37.48 |
| Daily Change: | -1.10 -2.85 |
| Daily Volume: | 3,923,944 |
| Market Cap: | US$2.520B |
November 07, 2024 October 09, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
